Skip to content

US · TYRA · BIOTECHNOLOGY

Tyra Biosciences, Inc. (TYRA) intrinsic value and stock valuation

$20.12as of 2026-11-21 · Mkt cap 1.53B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Tyra Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values TYRA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TYRA’s statements →

Tyra Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Carlsbad, CA 92008 tyra.bio

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-119.95M
20192025
Free cash flow
-$-95.28M
20192025
Total equity
$259.2M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-132.76M-$-104.18M-$-79.94M-$-58.93M-$-26.29M
Net income-$-119.95M-$-86.48M-$-69.13M-$-55.33M-$-26.29M
EPSd-$-2.01M-$-1.51M-$-1.62M-$-1.32M-$-634.41K
Operating cash flow-$-95.14M-$-69.77M-$-50.14M-$-50.28M-$-23.75M
Capital expenditure-$-140K-$-660K-$-770K-$-560K-$-660K
Free cash flow-$-95.28M-$-70.44M-$-50.91M-$-50.84M-$-24.41M
Total assets$282.6M$363.6M$225.9M$266.2M$306.7M
Total debt$5.81M$6.22M$6.5M$2.62M$1.18M
Net debt-$-71.58M-$-85.74M-$-51.51M-$-248.59M-$-301M
Total equity$259.2M$343.2M$204.3M$257.8M$301.7M
Cash and short-term investments$256M$341.4M$203.5M$251.2M$302.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$102.9M$80.1M$62.5M$43M$20.6M
Selling, general and administrative expenses$29.8M$24.1M$17.4M$15.9M$5.65M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$132.8M$104.2M$79.9M$58.9M$26.3M
Cost and expenses$132.8M$104.2M$79.9M$58.9M$26.3M
Interest income$12.8M$17.7M$10.8M$3.65M$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$550K$520K$360K$300K$140K
Ebitda-$-119.4M-$-85.96M-$-68.78M-$-55.03M-$-26.15M
Operating income-$-132.76M-$-104.18M-$-79.94M-$-58.93M-$-26.29M
Total other income/expenses, net$12.8M$17.7M$10.8M$3.6M-$-10K
Income before tax-$-119.95M-$-86.48M-$-69.13M-$-55.33M-$-26.29M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-119.95M-$-86.48M-$-69.13M-$-55.33M-$-26.29M
Weighted average shares outstanding$59.6M$57.2M$42.7M$41.9M$41.4M
Weighted average diluted shares outstanding$59.6M$57.2M$42.7M$41.9M$41.4M
Balance sheet
20252024202320222021
Cash and short-term investments$256M$341.4M$203.5M$251.2M$302.2M
Net receivables$0.00$2M$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$265.5M$347.5M$211.7M$257.3M$304.1M
Property, plant and equipment, net$6.89M$7.72M$8.15M$3.54M$2.09M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$17.2M$16.1M$14.2M$8.89M$2.64M
Total assets$282.6M$363.6M$225.9M$266.2M$306.7M
Accounts payable$1.18M$590K$4.66M$1.15M$600K
Short-term debt$470K$410K$280K$140K$200K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$18.1M$14.6M$15.3M$5.7M$3.62M
Long-term debt$5.34M$5.81M$6.22M$2.48M$980K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.34M$5.81M$6.26M$2.65M$1.35M
Capital lease obligations$0.00$5.81M$6.5M$2.62M$1.18M
Total liabilities$23.4M$20.4M$21.6M$8.35M$4.96M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-371.26M-$-251.31M-$-164.83M-$-95.7M-$-40.37M
Accumulated other comprehensive income (loss)$390K$770K$380K$0.00$0.00
Total equity$259.2M$343.2M$204.3M$257.8M$301.7M
Total investments$178.6M$249.5M$145.5M$0.00$0.00
Total debt$5.81M$6.22M$6.5M$2.62M$1.18M
Net debt-$-71.58M-$-85.74M-$-51.51M-$-248.59M-$-301M
Cash flow statement
20252024202320222021
Net income-$-119.95M-$-86.48M-$-69.13M-$-55.33M-$-26.29M
Depreciation and amortization$550K$520K$360K$300K$140K
Stock-based compensation$28M$22.8M$13.5M$10.6M$2.89M
Change in working capital-$-1.63M-$-730K$6.36M-$-5.85M-$-480K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$1.49M
Net cash provided by operating activities-$-95.14M-$-69.77M-$-50.14M-$-50.28M-$-23.75M
Investments in property, plant and equipment-$-140K-$-660K-$-770K-$-560K-$-660K
Acquisitions, net$0.00$0.00$0.00$0.00$20K
Net cash used for investing activities$72.5M-$-98.4M-$-144.6M-$-560K-$-650K
Common stock issued$8.1M$200M$1.54M$630K$181.2M
Common stock repurchased$0.00-$-420K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.1M$202.1M$1.54M$630K$311.4M
Net change in cash-$-14.58M$34M-$-193.21M-$-50.97M$287M
Cash at end of period$78.4M$93M$58M$251.2M$302.4M
Operating cash flow-$-95.14M-$-69.77M-$-50.14M-$-50.28M-$-23.75M
Capital expenditure-$-140K-$-660K-$-770K-$-560K-$-660K
Free cash flow-$-95.28M-$-70.44M-$-50.91M-$-50.84M-$-24.41M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Tyra Biosciences, Inc.

        Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

        CEO
        Todd Harris
        Employees
        87
        Beta
        0.76

        Explore

        Frequently asked questions

        What is the intrinsic value of Tyra Biosciences, Inc. (TYRA)?

        InvestorsCraft does not currently publish an intrinsic value for TYRA. How the IC value is calculated.

        Is TYRA undervalued?

        InvestorsCraft does not publish an undervaluation signal for TYRA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.